Effectiveness of nirmatrelvir plus ritonavir treatment for patients with CLL during the Omicron Surge

Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée à la COVID-19

Résumé en anglais

Patients with CLL, even in the omicron era and post-vaccination, suffer from persistent covid, higher complications and mortality compared to the general population. In the current study, we evaluated retrospectively the effectiveness of Nirmatrelvir plus ritonavir among 1,080 patients with CLL that were infected with SARS-CoV-2. Nirmatrelvir administration was associated with a reduction in Covid-19-related hospitalization or death by day 35. Specifically, the rate of Covid-19-related hospitalization or death in the treated group compared to the untreated group was 4.8% (14 out of 292) versus 10.2% (75 out of 733). Moreover, we report a 69% relative risk reduction in Covid-19-related hospitalization or death in patients with CLL at the age of 65 years or above. Multivariate analysis indicates that patients older than 65 years, heavily treated patients (>2 prior treatments), patients with recent hospitalizations, IVIG treatment and comorbidity had significant improvement outcomes following treatment with Nirmatrelvir.